RAR-related orphan receptor gamma agonist - Eternity Bioscience
Alternative Names: RORγ agonist - Eternity BioscienceLatest Information Update: 28 May 2024
Price :
$50 *
At a glance
- Originator Eternity Bioscience
- Class Antineoplastics; Small molecules
- Mechanism of Action Nuclear receptor subfamily 1 group F member 3 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in Cancer in USA
- 09 Apr 2020 RAR-related orphan receptor gamma agonist - Eternity Bioscience is available for licensing as of 09 Apr 2020. https://www.eternitybioscience.com/pipeline
- 09 Apr 2020 Preclinical trials in Cancer in USA (unspecified route), prior to April 2020 (Eternity Bioscience pipeline, April 2020)